GTx To File NDA For Acapodene In Early 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III interim analysis finds the selective estrogen receptor modulator lowers cholesterol associated with androgen deprivation therapy for prostate cancer.